Strong Revenue Growth
Third quarter revenue totaled $224.5 million, a 10% increase compared to the prior year period. U.S. revenue was $214.4 million, a 9% increase, and revenue outside the U.S. was $10.1 million, a 37% increase year-over-year.
Improved Gross Margin
Gross margin in the quarter was 85.8% compared to 84.1% in the prior year period, primarily due to increased sales volume and increased sales mix of Inspire V.
Positive Clinical Outcomes
The Singapore clinical study demonstrated significant performance improvement with a 20% reduction in surgical times. U.S. Limited-Market-Release showed a clinically relevant reduction in disease severity.
Increased Earnings Guidance
Earnings per share guidance increased to $0.90 to $1, up from $0.40 to $0.50 previously.
Reimbursement Improvements
CMS finalized the 2026 physician fee schedule at approximately $660, an 11% increase for CPT code 64568, effective January 1, 2026.